Home — Products — Recombinant Peptides
ProductRecombinant Peptides
Custom and catalog recombinant peptides expressed and purified to defined purity thresholds for research and formulation work.
What you are buying
Peptide programmes live or die on purity and stability. We express, purify and characterize peptides with the analytical package attached — including the forced degradation and stability data formulation work will need later.
- GLP-1 and metabolic peptide programmes
- Biosimilar peptide development
- Formulation and stability screening
- Pre-clinical study material
PepXen™ — high expression, lower COGS.
Our proprietary PepXen™ platform expresses recombinant peptides at high yield in a smaller footprint — more product, less volume, better economics for insulin, GLP-1 and other recombinant peptides.
Recombinant peptide programmes.
Expression-based (not synthetic) peptide programmes developed on the PepXen™ platform. See our full pipeline for development stages.
Insulin Aspart
Rapid-acting insulin analogue.
Insulin Glargine
Long-acting insulin analogue.
Human Insulin
Recombinant human insulin.
Insulin Lispro
Rapid-acting insulin analogue.
Insulin Degludec
Ultra-long-acting insulin analogue.
Semaglutide
GLP-1 receptor agonist for type-2 diabetes and obesity.
Liraglutide
GLP-1 receptor agonist for type-2 diabetes and obesity.
Dulaglutide
GLP-1 receptor agonist.
Development stages reflect current technical progress and do not imply regulatory approval or commercial availability.
Every peptide, in detail.
Each molecule in our recombinant-peptide pipeline, expressed on the PepXen™ platform, with its role and development stage.
Insulin Aspart
A rapid-acting insulin analogue expressed recombinantly on the PepXen™ platform. At an advanced stage of development, with expression and purification established for a scalable, high-yield process.
Enquire about Insulin AspartInsulin Glargine
A long-acting basal insulin analogue. Advanced-stage development on PepXen™, engineered for consistent yield and a clean impurity profile.
Enquire about Insulin GlargineHuman Insulin
Recombinant human insulin, the foundation molecule of diabetes care, produced by expression rather than extraction. Advanced-stage development.
Enquire about Human InsulinInsulin Lispro
A rapid-acting insulin analogue. Advanced-stage development on the PepXen™ high-expression platform.
Enquire about Insulin LisproInsulin Degludec
An ultra-long-acting insulin analogue. In development, extending Theertha’s insulin franchise toward the newest basal analogues.
Enquire about Insulin DegludecSemaglutide
A GLP-1 receptor agonist for type-2 diabetes and weight management — among the most in-demand molecules in the world. Advanced-stage recombinant development on PepXen™.
Enquire about SemaglutideLiraglutide
A GLP-1 receptor agonist for type-2 diabetes and obesity. Advanced-stage development on the recombinant peptide platform.
Enquire about LiraglutideDulaglutide
A long-acting GLP-1 receptor agonist. In development on Theertha’s recombinant peptide platform.
Enquire about DulaglutideDevelopment stages reflect current technical progress and do not imply regulatory approval or commercial availability. Vial imagery is an illustrative representation of Theertha development material, not finished commercial product.
Other product lines.
Need a custom specification?
Most of what we supply is programme-specific. Send us the requirement and we will confirm feasibility, timeline and price.